JP2004534093A - フルベストラントの筋肉内投与用の医薬製剤 - Google Patents
フルベストラントの筋肉内投与用の医薬製剤 Download PDFInfo
- Publication number
- JP2004534093A JP2004534093A JP2003511869A JP2003511869A JP2004534093A JP 2004534093 A JP2004534093 A JP 2004534093A JP 2003511869 A JP2003511869 A JP 2003511869A JP 2003511869 A JP2003511869 A JP 2003511869A JP 2004534093 A JP2004534093 A JP 2004534093A
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- weight
- volume
- fulvestrant
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0116619.8A GB0116619D0 (en) | 2001-07-07 | 2001-07-07 | Formulation |
US31571101P | 2001-08-30 | 2001-08-30 | |
PCT/GB2002/003092 WO2003006064A1 (en) | 2001-07-07 | 2002-07-03 | Pharmaceutical formulation for the intramuscular administration of fulvestrant |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2004534093A true JP2004534093A (ja) | 2004-11-11 |
Family
ID=26246290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003511869A Pending JP2004534093A (ja) | 2001-07-07 | 2002-07-03 | フルベストラントの筋肉内投与用の医薬製剤 |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1406662A1 (xx) |
JP (1) | JP2004534093A (xx) |
CN (1) | CN1553815A (xx) |
AR (1) | AR037138A1 (xx) |
BR (1) | BR0210898A (xx) |
CA (1) | CA2453111A1 (xx) |
CO (1) | CO5560585A2 (xx) |
HU (1) | HUP0400115A3 (xx) |
IL (1) | IL159576A0 (xx) |
IS (1) | IS7097A (xx) |
MX (1) | MXPA04000028A (xx) |
NO (1) | NO20040047L (xx) |
PL (1) | PL367624A1 (xx) |
RU (1) | RU2004102393A (xx) |
WO (1) | WO2003006064A1 (xx) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015511606A (ja) * | 2012-03-31 | 2015-04-20 | リポント ファーマシューティカルズ インコーポレイテッド | 乳酸エステルをベースとするフルベストラント又はその誘導体の油性製剤およびその製造方法 |
WO2017175810A1 (ja) * | 2016-04-06 | 2017-10-12 | 富士フイルム株式会社 | 医薬組成物 |
JP2019516789A (ja) * | 2016-05-06 | 2019-06-20 | イーグル ファーマスーティカルズ、インク. | フルベストラント配合物およびその使用方法 |
US10668083B2 (en) | 2016-05-31 | 2020-06-02 | Fujifilm Corporation | Pharmaceutical composition |
JP2021502362A (ja) * | 2017-11-08 | 2021-01-28 | イーグル ファーマスーティカルズ、インク. | フルベストラント製剤とその使用方法 |
JP2023504867A (ja) * | 2019-12-11 | 2023-02-07 | 上海博志研新薬物技術有限公司 | フルベストラント医薬組成物、その調製方法及び応用 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
US8586092B2 (en) | 2009-08-31 | 2013-11-19 | Xi'an Libang Pharmaceutical Technology Co., Ltd. | Fulvestrant nanosphere/microsphere and preparative method and use thereof |
CN102600065B (zh) * | 2012-03-31 | 2014-08-13 | 莱普德制药有限公司 | 一种氟维司群或其衍生物油性制剂及其制备方法 |
CN102600064A (zh) * | 2012-03-31 | 2012-07-25 | 西安力邦制药有限公司 | 氟维司群或其衍生物缓释制剂及其制备方法 |
US9271990B2 (en) | 2014-02-14 | 2016-03-01 | Fresenius Kabi Usa, Llc | Fulvestrant formulations |
US11590077B2 (en) | 2016-05-06 | 2023-02-28 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
WO2019113361A1 (en) * | 2017-12-07 | 2019-06-13 | Nevakar Inc. | Concentrated fulvestrant compositions |
WO2019151353A1 (ja) * | 2018-01-31 | 2019-08-08 | 富士フイルム株式会社 | 注射用製剤の製造方法 |
CN111481559B (zh) * | 2019-01-25 | 2021-10-08 | 江苏恒瑞医药股份有限公司 | 一种高浓度的氟维司群组合物及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8813353D0 (en) * | 1988-06-06 | 1988-07-13 | Ici Plc | Therapeutic product |
GB9525194D0 (en) * | 1995-12-12 | 1996-02-07 | Zeneca Ltd | Pharmaceutical composition |
GB0000313D0 (en) * | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
GB0008172D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Therapy |
-
2002
- 2002-07-03 PL PL02367624A patent/PL367624A1/xx not_active Application Discontinuation
- 2002-07-03 IL IL15957602A patent/IL159576A0/xx unknown
- 2002-07-03 BR BR0210898-4A patent/BR0210898A/pt not_active IP Right Cessation
- 2002-07-03 CN CNA028171888A patent/CN1553815A/zh active Pending
- 2002-07-03 RU RU2004102393/15A patent/RU2004102393A/ru not_active Application Discontinuation
- 2002-07-03 EP EP02740940A patent/EP1406662A1/en not_active Withdrawn
- 2002-07-03 CA CA002453111A patent/CA2453111A1/en not_active Abandoned
- 2002-07-03 JP JP2003511869A patent/JP2004534093A/ja active Pending
- 2002-07-03 WO PCT/GB2002/003092 patent/WO2003006064A1/en not_active Application Discontinuation
- 2002-07-03 HU HU0400115A patent/HUP0400115A3/hu unknown
- 2002-07-05 AR ARP020102523A patent/AR037138A1/es not_active Application Discontinuation
-
2004
- 2004-01-05 IS IS7097A patent/IS7097A/is unknown
- 2004-01-06 NO NO20040047A patent/NO20040047L/no not_active Application Discontinuation
- 2004-01-07 MX MXPA04000028A patent/MXPA04000028A/es unknown
- 2004-01-07 CO CO04000761A patent/CO5560585A2/es not_active Application Discontinuation
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015511606A (ja) * | 2012-03-31 | 2015-04-20 | リポント ファーマシューティカルズ インコーポレイテッド | 乳酸エステルをベースとするフルベストラント又はその誘導体の油性製剤およびその製造方法 |
US10568890B2 (en) | 2012-03-31 | 2020-02-25 | Xi'an Libang Pharmaceutical Co., Ltd | Lactate-based fulvestrant or fulvestrant derivative oily preparation and preparation method thereof |
WO2017175810A1 (ja) * | 2016-04-06 | 2017-10-12 | 富士フイルム株式会社 | 医薬組成物 |
JPWO2017175810A1 (ja) * | 2016-04-06 | 2018-12-20 | 富士フイルム株式会社 | 医薬組成物 |
US10772895B2 (en) | 2016-04-06 | 2020-09-15 | Fujifilm Corporation | Pharmaceutical composition |
JP2019516789A (ja) * | 2016-05-06 | 2019-06-20 | イーグル ファーマスーティカルズ、インク. | フルベストラント配合物およびその使用方法 |
US10668083B2 (en) | 2016-05-31 | 2020-06-02 | Fujifilm Corporation | Pharmaceutical composition |
JP2021502362A (ja) * | 2017-11-08 | 2021-01-28 | イーグル ファーマスーティカルズ、インク. | フルベストラント製剤とその使用方法 |
JP7220712B2 (ja) | 2017-11-08 | 2023-02-10 | イーグル ファーマスーティカルズ、インク. | フルベストラント製剤とその使用方法 |
JP2023504867A (ja) * | 2019-12-11 | 2023-02-07 | 上海博志研新薬物技術有限公司 | フルベストラント医薬組成物、その調製方法及び応用 |
JP7497902B2 (ja) | 2019-12-11 | 2024-06-11 | 上海雲晟研新生物科技有限公司 | フルベストラント医薬組成物、その調製方法及び応用 |
Also Published As
Publication number | Publication date |
---|---|
HUP0400115A3 (en) | 2005-11-28 |
EP1406662A1 (en) | 2004-04-14 |
PL367624A1 (en) | 2005-03-07 |
MXPA04000028A (es) | 2004-05-21 |
IS7097A (is) | 2004-01-05 |
RU2004102393A (ru) | 2005-03-27 |
AR037138A1 (es) | 2004-10-27 |
WO2003006064A1 (en) | 2003-01-23 |
NO20040047L (no) | 2004-02-23 |
HUP0400115A2 (hu) | 2004-06-28 |
CO5560585A2 (es) | 2005-09-30 |
CN1553815A (zh) | 2004-12-08 |
BR0210898A (pt) | 2004-06-22 |
CA2453111A1 (en) | 2003-01-23 |
IL159576A0 (en) | 2004-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3713237B2 (ja) | フルベストラント製剤 | |
JP2004534093A (ja) | フルベストラントの筋肉内投与用の医薬製剤 | |
JP4295087B2 (ja) | フルベストラントを含む製剤 | |
KR20040010841A (ko) | 풀베스트란트의 근육내 주사용 약학 제제 | |
AU2002314368A1 (en) | Pharmaceutical formulation for the intramuscular administration of fulvestrant |